 NEW YORK, July 29, 2021 GLOBE NEWSWIRE -- Cellectis S.A. NASDAQ: CLLS EURONEXT GROWTH: ALCLS the Company, a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor CAR T-cells and gene therapy programs for monogenic diseases, announced that it will report its financial results for the second quarter and first six-month period ending June 30, 2021, on Thursday, August 5, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EDT 2:00 PM CET on Friday, August 6, 2021, prior to the open of the US market. 